Chinese National Medical Products Administration (NMPA) has approved CooperVisionMiSight 1 day contact lenses in China.
FREMONT, CA: Following a priority evaluation, the Chinese National Medical Products Administration (NMPA), which oversees medical devices and pharmaceuticals, has certified CooperVisionMiSight 1 day contact lenses for use in China. The groundbreaking soft contact lenses are now the first product to be approved in China for slowing the axial length development.
"Everyone at CooperVision is committed to combatting the increasing prevalence and severity of myopia among children. It has become one of the world's most pressing global eye health issues" with implications for generations to come," said Daniel G. McBride, President, CooperVision. "We are enthusiastic about MiSight® 1 day contact lenses impact in partnership with highly-knowledgeable ophthalmologists and health care leaders across China. This development will further expand the global reach of our evidence-based technologies and clinical successes."
By 2050, myopia, commonly referred to as nearsightedness and short-sightedness, is expected to impact the eyesight of about five billion individuals and increase ocular health hazards by more than doubling current numbers. Future vision-threatening disorders like cataracts, retinal detachment, glaucoma, and myopic maculopathy have been associated to myopic progression.
In recent years, the prevalence of myopia has risen dramatically in China. Myopia affects 14.3 percent of children under the age of six, whereas it affects 80.5 percent of high school students.
Myopia prevalence climbed 2.5 percent in China from 2019 to 2020, owing to children spending more time indoors and using digital screens. Myopia rates in primary schools constantly increase as children become older, going from 12.9 percent in first grade to 59.6 percent in sixth. Myopia increased by 9.3 percentage points for every step on average.
Global Myopia Management Leadership
CooperVision has been at the frontline of developing the worldwide myopia management category for more than a decade, working in collaboration with the optometry and ophthalmology communities to aid numerous children and their caretakers.
MiSight 1 day contact lenses from CooperVision are currently accessible in more than 25 countries. They were the first and only FDA-approved soft contact lenses for myopia control in the United States, with a proven capacity to reduce the growth of nearsightedness in children between the ages of 8 to 12 at the time of treatment. The lenses are the cornerstone for the organization's Brilliant Futures Myopia Management Program, which is only offered in a few countries.